The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKainos Group Regulatory News (KNOS)

Share Price Information for Kainos Group (KNOS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 992.00
Bid: 993.00
Ask: 999.00
Change: -5.00 (-0.50%)
Spread: 6.00 (0.604%)
Open: 993.00
High: 1,004.00
Low: 988.00
Prev. Close: 997.00
KNOS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

16 Mar 2016 07:00

RNS Number : 2050S
Kainos Group plc
16 March 2016
 

ANNOUNCEMENT

 

16 March 2016

 

Kainos Group plc

 

("Kainos" or "the Company")

 

Trading Update and transition to Evolve SaaS delivery model

 

Company performance in-line with expectations for year ending 31 March 2016

 

Kainos Group plc (LSE:KNOS), a leading UK-based provider of IT, consulting and software solutions, today issues a trading update for the year ending 31 March 2016. The Board expects results for the full year to be in-line with market expectations.

 

Current Trading

In the public sector, Kainos continues to see an improvement in market conditions. This is expected to result in a further gradual increase in opportunities across government departments such as the Ministry of Justice, where Kainos is providing support for an ambitious reform programme, and at the Office of National Statistics (ONS), where the Company has recently been awarded a new contract to work jointly with the client to provide comprehensive registers to improve the quality and cost effectiveness of the 2021 UK census. The Company remains optimistic around the increasing drive for digitisation in the NHS and other government departments and believes that its Digital Services and Evolve divisions are well-placed to benefit from these positive market dynamics.

 

Outside government, the Company is encouraged by opportunities in its Evolve and WorkSmart divisions, particularly in the US and mainland Europe, where it has established offices in Boston and Amsterdam. The Company's WorkSmart division is experiencing a growing pipeline of opportunities for both its services implementation business, largely centred in the UK and mainland Europe, and its SaaS-based automated testing product, Kainos Smart. At March 7, the Company had 56 customers using Kainos Smart, including Shire Pharmaceuticals and Mizuho Bank, and has recently won its first mainland European prime engagement contract in the Netherlands.

 

Transition to Evolve SaaS delivery model

In Evolve, customers are showing a significantly greater interest in a SaaS delivery model rather than in the perpetual licence model currently offered. Recent SaaS wins include InTouch Health, a leading provider of telehealth solutions, which as separately announced today signed a five-year agreement to deploy the Evolve Integrated Care SaaS platform to support telehealth applications in over 1,500 hospitals in the US and Europe, and the recently announced partnership with Cirdan Imaging Limited, a privately-owned supplier of medical diagnostic hardware and software, which in February licenced the Evolve SaaS product for five years. In a landmark deal in the UK, Kainos Evolve has also been selected as a preferred supplier to provide the Evolve Integrated Care platform to a major Clinical Commissioning Group (CCG).

 

Such SaaS contracts provide Kainos with greater revenue visibility and more durable, longer-term client relationships. To capitalise on these and similar opportunities, the Company plans to invest further in both product development and sales and marketing. These two initiatives, particularly the transition to SaaS, while improving the quality of Evolve's future earnings, are however likely to have a short-term impact on Evolve's revenue, profits and cash generation in the financial year ending 31 March 2017. The Directors believe this change to the Evolve delivery model is in the best interests of the Company in maximising Evolve's market penetration.

 

The Company has a strong balance sheet with strong reserves, no debt and strong cash generation, as well as a growing level of recurring revenue. Recruitment remains strong, with 39 people joining Kainos in January alone, and the Company's position rose for the sixth consecutive year to 37th place in the 'Sunday Times Best Companies to Work For'.

 

Investor/analyst event

 

Kainos will hold a Capital Markets Day for investors and analysts on Tuesday 19 April 2016 to explore in more detail the drivers of the Company's current and future success. 

 

-ENDS-

 

For further information, please contact:

Kainos via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Brian Gannon, SVP Corporate Development

 

Investec Bank plc +44 20 7597 0000

Dominic Emery/Sebastian Lawrence

Patrick Robb/Matt Lewis

 

FTI Consulting LLP +44 20 3727 1000

Matt Dixon/Chris Lane

 

About Kainos

Kainos is a UK-based provider of IT services, consulting and software solutions. The Group specialises across multiple sectors in the development of digital technology solutions, including software design and agile software development. The company's Evolve Electronic Medical Records (EMR) product provides a market-leading comprehensive suite of digital services to healthcare providers such as hospitals and community care organisations. Kainos has also developed an automated testing product, Smart, to complement its Workday implementation services.

 

Kainos Group plc (KNOS) is listed on the main market of the London Stock Exchange. At 30 December 2015, it had almost 800 staff working in eight offices in the USA, UK, Ireland, Poland and the Netherlands.

 

For further information please visit the company website: https://www.kainos.com/

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTJAMRTMBBBBTF
Date   Source Headline
1st May 202412:00 pmRNSTotal Voting Rights
15th Apr 20247:00 amRNSYear-end Trading Update
11th Apr 20243:50 pmRNSHolding(s) in Company
2nd Apr 202412:12 pmRNSTotal Voting Rights
15th Mar 20241:48 pmRNSHolding(s) in Company
28th Feb 20243:16 pmRNSHolding(s) in Company
5th Feb 202412:51 pmRNSHolding(s) in Company
1st Feb 20244:29 pmRNSHolding(s) in Company
1st Feb 20244:21 pmRNSHolding(s) in Company
1st Feb 202412:13 pmRNSTotal Voting Rights
31st Jan 20244:09 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:15 pmRNSTotal Voting Rights
22nd Dec 20239:21 amRNSExecutive Director PSP Award/PDMR shareholdings
1st Dec 20239:35 amRNSTotal Voting Rights
17th Nov 202311:13 amRNSExecutive Director PSP Award/PDMR shareholdings
13th Nov 20237:00 amRNSInterim Results
1st Nov 202310:48 amRNSTotal Voting Rights
2nd Oct 202312:41 pmRNSTotal Voting Rights
2nd Oct 20237:00 amRNSConfirmation of Board Changes
27th Sep 20235:52 pmRNSDirector/PDMR Shareholding
21st Sep 20232:54 pmRNSResults of Annual General Meeting
21st Sep 202311:59 amRNSConfirmation of CEO appointment
1st Sep 202312:34 pmRNSTotal Voting Rights
31st Aug 20237:00 amRNSTrading Update
10th Aug 20232:48 pmRNSNotice of AGM
3rd Aug 202310:41 amRNSMount Charles & Bankmore Square, Belfast
1st Aug 20234:02 pmRNSHolding(s) in Company
1st Aug 20233:58 pmRNSTotal Voting Rights
21st Jul 20235:11 pmRNSAnnual Report 2023
3rd Jul 20231:20 pmRNSTotal Voting Rights
3rd Jul 20237:00 amRNSAcquisition of RapidIT-Cloudbera, Inc.
23rd Jun 202312:55 pmRNSDirector/PDMR Shareholding
19th Jun 20237:00 amRNSPlanned CEO Transition
1st Jun 202311:23 amRNSTotal Voting Rights
23rd May 20234:36 pmRNSHolding(s) in Company
22nd May 20237:00 amRNSFinal Results
3rd May 20235:21 pmRNSHolding(s) in Company
2nd May 20237:00 amRNSAppointment of Independent Non-Executive Director
19th Apr 20237:00 amRNSTrading Statement
3rd Apr 20232:30 pmRNSTotal Voting Rights
17th Mar 20235:05 pmRNSHolding(s) in Company
1st Mar 202312:07 pmRNSTotal Voting Rights
1st Feb 20239:35 amRNSTotal Voting Rights
30th Dec 20229:53 amRNSTotal Voting Rights
29th Dec 202210:20 amRNSHolding(s) in Company
21st Dec 20224:58 pmRNSHolding(s) in Company
20th Dec 20224:15 pmRNSDirector/PDMR Shareholding
7th Dec 20228:40 amRNSHolding(s) in Company
1st Dec 202212:10 pmRNSTotal Voting Rights
18th Nov 20224:38 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.